Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C.
Lévesque E, et al. Among authors: droit a.
Br J Cancer. 2020 Mar;122(7):1068-1076. doi: 10.1038/s41416-020-0749-2. Epub 2020 Feb 12.
Br J Cancer. 2020.
PMID: 32047296
Free PMC article.